Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE DE LA CERDA

Allopathic & Osteopathic Physicians Urology

NPI
1881038412
CMS profile
5298480
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$20,403.74

95 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE DE LA CERDA

NPI 1881038412 · CMS profile ID 5298480

Allopathic & Osteopathic Physicians / Urology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881038412?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE DE LA CERDA, NPI 1881038412, CMS profile ID 5298480. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881038412?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOSE DE LA CERDA, NPI 1881038412, CMS profile ID 5298480. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881038412?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOSE DE LA CERDA, NPI 1881038412, CMS profile ID 5298480, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1881038412?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

95 matching records · $20,403.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 95 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–95 of 95.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $157.0705/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753239 CMS
Janssen Biotech, Inc. $206.7005/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753241 CMS
Janssen Biotech, Inc. $8.0005/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753243 CMS
Janssen Biotech, Inc. $390.7705/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753245 CMS
Janssen Biotech, Inc. $124.4905/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753247 CMS
Janssen Biotech, Inc. $21.5705/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753249 CMS
Janssen Biotech, Inc. $194.7005/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753251 CMS
Janssen Biotech, Inc. $4,125.0005/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753253 CMS
Janssen Biotech, Inc. $14.4205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753255 CMS
Janssen Biotech, Inc. $625.0505/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753257 CMS
Axonics, Inc. $14.3305/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801913 CMS
Sun Pharmaceutical Industries Inc. $19.1305/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053877437 CMS
Janssen Biotech, Inc. $149.4604/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753265 CMS
Sumitomo Pharma America, Inc. $35.5704/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030964733 CMS
Axonics, Inc. $5.7904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801911 CMS
Novartis Pharmaceuticals Corporation $12.9804/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991495099 CMS
Amgen Inc. $17.9504/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019976533 CMS
Axonics, Inc. $131.6504/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801909 CMS
UroGen Pharma, Inc. $17.3204/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038584615 CMS
Janssen Biotech, Inc. $4,125.0004/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753227 CMS
Janssen Biotech, Inc. $334.0504/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753229 CMS
Janssen Biotech, Inc. $5.9204/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753231 CMS
Janssen Biotech, Inc. $124.9104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753233 CMS
Sumitomo Pharma America, Inc. $30.4804/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030964775 CMS
PFIZER INC. $18.0103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049746955 CMS
Axonics, Inc. $8.8203/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801847 CMS
Axonics, Inc. $13.9203/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801895 CMS
Axonics, Inc. $9.6103/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801893 CMS
Axonics, Inc. $257.6303/15/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051802017 CMS
Janssen Biotech, Inc. $19.3403/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753263 CMS
Axonics, Inc. $12.2803/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801855 CMS
Sumitomo Pharma America, Inc. $25.8103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030964741 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.2302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000900741 CMS
Janssen Biotech, Inc. $550.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753225 CMS
Axonics, Inc. $6.5002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801837 CMS
PFIZER INC. $11.2202/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049543111 CMS
Axonics, Inc. $16.0302/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801833 CMS
Merck Sharp & Dohme LLC $32.3102/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048465437 CMS
Janssen Biotech, Inc. $550.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753235 CMS
Janssen Biotech, Inc. $19.2401/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988753261 CMS
UroGen Pharma, Inc. $21.2601/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038626035 CMS
Amgen Inc. $15.4601/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019976531 CMS
Axonics, Inc. $6.8501/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051801831 CMS
PFIZER INC. $18.7801/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049118195 CMS
Sumitomo Pharma America, Inc. $27.0601/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030964737 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,726.86 44
PY2020 $1,753.63 16
PY2021 $6,552.38 41
PY2022 $16,663.08 82
PY2023 $20,403.74 95
PY2024 $40,929.10 111
PY2025 $189,503.39 253

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,649.34 2
PY2025 Principal investigator $3,832,990.81 92
PY2024 Principal investigator $3,563,460.67 65
PY2023 Recipient $2,216.20 1
PY2023 Principal investigator $264,018.53 26
PY2022 Recipient $1,382.00 1
PY2022 Principal investigator $1,006,517.79 26
PY2021 Principal investigator $46,544.20 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $981.83 12/31/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228731215
Principal investigator 1 PFIZER INC. $4,522.05 12/31/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228745340
Principal investigator 1 PFIZER INC. $46,207.89 12/29/2025 Non-covered Recipient Entity
Urology San Antonio USA Clinical Trials
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228716871
Principal investigator 1 PFIZER INC. $338.65 12/16/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228736527
Principal investigator 1 PFIZER INC. $30,805.26 12/15/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228714463
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,149.40 12/01/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190306613
Principal investigator 1 PFIZER INC. $3,327.35 11/26/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228727145
Principal investigator 1 PFIZER INC. $981.83 11/26/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228737377
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,327.09 11/25/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305029
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,754.65 11/15/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306615
Principal investigator 1 AstraZeneca UK Limited $18,349.20 11/14/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate No dispute reported 06/30/2026 1185553535
Principal investigator 1 PFIZER INC. $16,525.90 11/14/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228728589
Principal investigator 1 PFIZER INC. $33,057.73 11/14/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228729170
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,628.00 11/05/2025 Non-covered Recipient Entity
Urology San Antonio, P.a.
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225408876
Principal investigator 1 PFIZER INC. $92,415.78 11/05/2025 Non-covered Recipient Entity
Urology San Antonio USA Clinical Trials
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717029
Principal investigator 1 PFIZER INC. $92,415.78 11/05/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718810
Principal investigator 1 Sumitomo Pharma America, Inc. $1,250.50 11/05/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654895
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654950
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655006
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 11/05/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655068
Principal investigator 1 PFIZER INC. $981.83 10/29/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228742307
Principal investigator 1 PFIZER INC. $3,585.40 10/21/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228740761
Principal investigator 1 PFIZER INC. $30,805.26 10/20/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228714535
Recipient Novartis Pharmaceuticals Corporation $5,055.17 10/15/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291292
Principal investigator 1 PFIZER INC. $1,963.66 10/15/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228741463
Principal investigator 1 PFIZER INC. $598.00 10/09/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228739890
Principal investigator 1 PFIZER INC. $92,415.78 10/06/2025 Non-covered Recipient Entity
Urology San Antonio USA Clinical Trials
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717191
Principal investigator 1 PFIZER INC. $92,415.78 10/06/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718808
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,380.00 09/25/2025 Non-covered Recipient Entity
Urology San Antonio, P.a.
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402483
Principal investigator 1 PFIZER INC. $206,560.65 09/24/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228750491
Principal investigator 1 PFIZER INC. $30,805.26 09/23/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228714533
Principal investigator 1 PFIZER INC. $7,925.46 09/16/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228720133
Principal investigator 1 PFIZER INC. $46,207.89 08/25/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228714537
Principal investigator 1 PFIZER INC. $936.65 08/23/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228784833
Principal investigator 1 PFIZER INC. $18,848.30 08/23/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228785889
Principal investigator 1 PFIZER INC. $1,900.00 08/22/2025 Non-covered Recipient Entity
Urology San Antonio PA
A LOWINTERVENTIONAL STUDY TO ASSESS GDF15 LEVELS IN ADULT PARTICIPANTS WITH CACHEXIA AND MALIGNANT SOLID TUMORS No dispute reported 06/30/2026 1228765840
Principal investigator 1 PFIZER INC. $2,163.86 08/14/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228785508
Principal investigator 1 PFIZER INC. $3,013.40 08/14/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228785723
Principal investigator 1 PFIZER INC. $92,415.78 08/13/2025 Non-covered Recipient Entity
Urology San Antonio USA Clinical Trials
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717189
Principal investigator 1 PFIZER INC. $92,415.78 08/13/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718883
Principal investigator 1 PFIZER INC. $3,927.32 08/09/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228761971
Principal investigator 1 Sumitomo Pharma America, Inc. $1,445.50 08/01/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641794
Principal investigator 1 Sumitomo Pharma America, Inc. $3,762.00 08/01/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641848
Principal investigator 1 PFIZER INC. $30,805.26 07/28/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228714461
Principal investigator 1 PFIZER INC. $1,196.00 07/25/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228785048
Principal investigator 1 PFIZER INC. $4,781.40 07/16/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228782102
Principal investigator 1 PFIZER INC. $92,415.78 07/14/2025 Non-covered Recipient Entity
Urology San Antonio USA Clinical Trials
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717187
Principal investigator 1 PFIZER INC. $92,415.78 07/14/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228719335
Principal investigator 1 Sumitomo Pharma America, Inc. $60.00 07/09/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640274
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 07/09/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640329
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $106,150.00 07/03/2025 Non-covered Recipient Entity
Urology San Antonio, P.a.
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402475
Principal investigator 1 PFIZER INC. $30,805.26 06/30/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228769965
Principal investigator 1 PFIZER INC. $3,186.56 06/26/2025 Non-covered Recipient Entity
Urology San Antonio PA
A LOWINTERVENTIONAL STUDY TO ASSESS GDF15 LEVELS IN ADULT PARTICIPANTS WITH CACHEXIA AND MALIGNANT SOLID TUMORS No dispute reported 06/30/2026 1228792249
Principal investigator 1 PFIZER INC. $800.00 06/24/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228761783
Principal investigator 1 PFIZER INC. $3,585.40 06/18/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228790736
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,270.79 06/15/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190308364
Principal investigator 1 PFIZER INC. $30,805.26 06/05/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228759552
Principal investigator 1 PFIZER INC. $48,028.86 05/30/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228773444
Principal investigator 1 PFIZER INC. $598.00 05/28/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228773206
Principal investigator 1 PFIZER INC. $7,793.00 05/23/2025 Non-covered Recipient Entity
Urology San Antonio PA
A LOWINTERVENTIONAL STUDY TO ASSESS GDF15 LEVELS IN ADULT PARTICIPANTS WITH CACHEXIA AND MALIGNANT SOLID TUMORS No dispute reported 06/30/2026 1228772100
Principal investigator 1 PFIZER INC. $4,781.40 05/14/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228782263
Principal investigator 1 PFIZER INC. $30,805.26 05/06/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228762104
Principal investigator 1 PFIZER INC. $2,907.92 05/06/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228772114
Principal investigator 1 PFIZER INC. $92,415.78 04/29/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228743484
Principal investigator 1 PFIZER INC. $92,415.78 04/29/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755103
Principal investigator 1 PFIZER INC. $92,415.78 04/21/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755994
Principal investigator 1 PFIZER INC. $92,415.78 04/21/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228756115
Principal investigator 1 PFIZER INC. $4,184.70 04/16/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228724348
Principal investigator 1 Sumitomo Pharma America, Inc. $3,841.50 04/09/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632855
Principal investigator 1 Sumitomo Pharma America, Inc. $3,807.00 04/09/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO PA DBA USA CLINICAL TRIALS
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632869
Principal investigator 1 PFIZER INC. $2,390.70 04/08/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228780165
Principal investigator 1 PFIZER INC. $1,738.89 04/05/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228780002
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $910.00 04/01/2025 Non-covered Recipient Entity
Medication Management Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402445
Principal investigator 1 PFIZER INC. $8,422.01 03/22/2025 Non-covered Recipient Entity
Urology San Antonio PA dba USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228797262
Principal investigator 1 PFIZER INC. $3,586.70 03/22/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228797765
Principal investigator 1 PFIZER INC. $46,207.89 03/18/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755502
Principal investigator 1 PFIZER INC. $46,207.89 03/18/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228756145
Principal investigator 1 PFIZER INC. $61,610.52 03/05/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228761705
Recipient Novartis Pharmaceuticals Corporation $594.17 02/25/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190291067
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,628.00 02/24/2025 Non-covered Recipient Entity
Urology San Antonio, P.a.
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402403
Principal investigator 1 PFIZER INC. $1,008.24 02/24/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228768849
Principal investigator 1 PFIZER INC. $3,925.35 02/22/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228769603
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $167,152.00 02/18/2025 Non-covered Recipient Entity
Urology San Antonio, P.a.
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402405
Principal investigator 1 PFIZER INC. $30,805.26 02/10/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228762053
Principal investigator 1 PFIZER INC. $92,415.78 02/04/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228754742
Principal investigator 1 PFIZER INC. $92,415.78 02/04/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228756234
Principal investigator 1 AstraZeneca Pharmaceuticals LP $711,967.06 01/29/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185553531
Principal investigator 1 PFIZER INC. $92,415.78 01/28/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228754738
Principal investigator 1 PFIZER INC. $92,415.78 01/27/2025 Non-covered Recipient Entity
Urology San Antonio
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755997
Principal investigator 1 PFIZER INC. $3,585.40 01/25/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228798981
Principal investigator 1 Novartis Pharmaceuticals Corporation $234,084.55 01/22/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190308362
Principal investigator 1 PFIZER INC. $1,008.24 01/20/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228769443
Principal investigator 1 PFIZER INC. $46,207.89 01/20/2025 Non-covered Recipient Entity
USA Clinical Trials
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228769816
Principal investigator 1 PFIZER INC. $6,575.40 01/15/2025 Non-covered Recipient Entity
Urology San Antonio PA
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228798583